The FLARE (Flurpiridaz vs. Rubidium Evaluation) Trial

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Enrollment: 60

Sponsor: University of California, Los Angeles

Location: West Los Angeles Veterans Affairs Medical Center Los Angeles California

Summary

This study seeks to evaluate if the diagnostic performance of 18F-flurpiridaz positron emission tomography (PET) myocardial perfusion imaging (MPI), given the radiotracer's properties, is non-inferior to the currently most widely utilized PET MPI radiopharmaceutical, 82Rb-chloride.

Eligibility Criteria

Inclusion Criteria: * Patient scheduled for a clinically indicated 82Rb-chloride PET MPI * Age ≥ 18 years * Ability to provide consent Exclusion Criteria: * Previous participation in a 18F-flurpiridaz clinical trial * Prior myocardial infarction * Prior coronary revascularization (percutaneous coronary intervention and/or coronary artery bypass grafting) * History of orthotopic heart transplantation * Inability to control heart rate \< 65 bpm * Frequent ventricular or atrial ectopy leading to irregular cardiac rhythm * Creatinine ≥ 1.4 mg/dL * Pregnant or breast-feeding status

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07761728). StuddyBuddy aggregates publicly available trial information.